By providing a platform for idea-sharing, Open Innovation Drug Discovery lowers the barrier for collaborations between investigators working inside and outside an organization. Free exchange of ideas between investigators across traditionally impregnable organizational walls contributes to the advancement of Science.
Through prior experience with the Phenotypic Drug Discovery program (PD2), Lilly has established a network with academic and biotech investigators outside our walls to provide them access to proprietary, disease-relevant phenotypic assays. Today, we expand this partnership with top global research talent by adding sophisticated in vitro target-based assays (TargetD2) through our Open Innovation Drug Discovery program.